The effect of maternal prolactin infusion during pregnancy on fetal adipose tissue development.
The present study determines whether maternal administration of prolactin (PRL) to dams promotes the abundance of the brown adipose tissue-specific uncoupling protein-1 (UCP1) in fetal and neonatal rat pups. Recombinant PRL (24 micro g/kg per day), or an equivalent volume of saline, were infused into dams (n=19 per group) throughout pregnancy from 12 h after mating. Interscapular brown adipose tissue was sampled either from fetuses at 19.5 days of gestation (term=21.5 days) or from neonatal rat pups at approximately 18 h after birth. The abundance of UCP1 was determined by immunoblotting on adipose tissue samples from individual pups and pooled from groups of pups. This analysis was complemented by immunocytochemistry on representative adipose tissue samples. Maternal PRL infusion resulted in a greater abundance of UCP1 in fetal rats at 19.5 days of gestation (control: 97.2+/-8.4% reference; PRL: 525.6+/-74.4% reference; P<0.001) and in neonates 18 h after birth. In contrast, the abundance of the outer mitochondrial membrane protein voltage-dependent anion channel was unaffected by PRL. Neonatal adipose tissue sampled from pups born to PRL-infused dams possessed fewer lipid droplets, but more UCP1, as determined by immunocytochemistry. Fetal, but not maternal, plasma leptin concentrations were also increased by maternal PRL administration. In conclusion, as rats are altricial, and the potential thermogenic activity of brown adipose tissue develops over the first few days of postnatal life, these changes prior to, and at the time of, birth implicate PRL in fetal and neonatal adipose tissue maturation.
Academic Division of Child Health, School of Human Development, Queen's Medical Centre, University Hospital, Nottingham NG7 2UH, UK.
H
H
Budge
A
A
Mostyn
V
V
Wilson
A
A
Khong
A M
AM
Walker
M E
ME
Symonds
T
T
Stephenson
D002001:Adipose Tissue, Brown / Q000737:chemistry / Q000196:embryology* / Q000648:ultrastructure; D000818:Animals; D000831:Animals, Newborn; D001833:Body Temperature Regulation / Q000502:physiology*; D002352:Carrier Proteins / Q000032:analysis; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D005865:Gestational Age; D007262:Infusions, Intravenous; D007473:Ion Channels; D020738:Leptin / Q000097:blood; D008565:Membrane Proteins / Q000032:analysis; D008928:Mitochondria / Q000737:chemistry; D024101:Mitochondrial Proteins; D011247:Pregnancy; D011388:Prolactin / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage; D018709:Statistics, Nonparametric; D000071256:Uncoupling Protein 1
D002352:Carrier Proteins; D007473:Ion Channels; D020738:Leptin; D008565:Membrane Proteins; D024101:Mitochondrial Proteins; D011994:Recombinant Proteins; C000604371:UCP1 protein, human; C000604373:Ucp1 protein, rat; D000071256:Uncoupling Protein 1; D011388:Prolactin